期刊文献+

中老年体检人群高密度脂蛋白胆固醇与骨密度的关系 被引量:2

Association between high density lipoprotein cholesterol and bone mineral density in the middle-aged and the elderly in Guizhou
原文传递
导出
摘要 目的了解高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)与骨密度之间的关系,为骨质疏松防治提供指导作用。方法随机选取2020年6—12月于贵州医科大学附属医院健康管理中心进行健康体检,年龄≥40岁的941名中老年人群作为研究对象。采用标准化问卷收集基本信息,并测定血脂水平及评估腰椎、股骨颈和大粗隆骨密度。Pearson相关及线性回归以确定HDL-C与骨密度的关系。结果骨质疏松组HDL-C平均值高于骨量减少和正常骨密度组(P<0.05)。回归分析调整其他变量后结果显示,HDL-C水平与腰椎、股骨颈、大粗隆间骨密度成负相关(β=-0.142,-0.094,-0.077,P<0.05);按体质量指数(body mass index,BMI)分组后这种负相关性在超重人群中表现更为明显(r=-0.248、-0.226、-0.169,P<0.05),而在BMI<24.0 kg/m^(2)和BMI≥28.0 kg/m^(2)组无相关,差异无统计学意义(P>0.05)。ROC曲线结果显示,当HDL-C≥1.21 mmol/L时,对骨质疏松结局的预测价值较好(AUC=0.663,P<0.01)。结论血清HDL-C水平与≥40岁中老年人群腰椎、股骨颈、粗隆间骨密度成负相关。HDL-C对骨密度的负相关性主要表现在24.0 kg/m^(2)≤BMI<28.0 kg/m^(2)人群。HDL-C≥1.21 mmol/L水平是骨质疏松的独立危险因素。 Objective To explore the association between high density lipoprotein cholesterol(HDL-C)and bone mineral density(BMD)in the middle-aged and the elderly,and to provide guidance for the prevention and treatment of osteoporosis.Methods A cross-sectional study was conducted among 941 healthy adults aged≥40 years,randomly selected from the health management center of our hospital who underwent physical examination from June to December 2020.Basic information was collected by standardized questionnaire.The levels of blood lipids and bone mineral density were measured.Pearson correlation and linear regression were used to determine the relationship between HDL-C and BMD.Results The average HDL-C level in osteoporosis group was higher than that in osteopenia group and normal BMD group(P<0.05).After adjusting other variables,regression analysis showed that the level of HDL-C was negatively correlated with the BMD of lumbar vertebrae,femoral neck and intertrochanter(β=-0.142,-0.094,-0.077,P<0.05),especially among subjects who were overweight(r=-0.248,-0.226,-0.169,P<0.05),while this negative correlation was not observed among those with BMI<24.0 kg/m^(2)or BMI≥28.0 kg/m^(2).The ROC curve showed that when HDL-C≥1.21 mmol/L,it had better predictive value for osteoporosis(AUC=0.663,P<0.05).Conclusions The serum level of HDL-C is negatively correlated with the BMD of lumbar vertebrae,femoral neck and intertrochanter in the middle-aged and the elderly,especially among those who are overweight.HDLC≥1.21 mmol/L is an independent risk factor for osteoporosis.
作者 安苗苗 陈兰兰 张娇艳 朱焱 许海娜 冉利梅 AN Miao-miao;CHEN Lan-lan;ZHANG Jiao-yan;ZHU Yan;XU Hai-na;RAN Li-mei(School of Public Health,the Key Laboratory of Environmental Pollution Monitoring and Disease Control,Ministry of Education,Guizhou Medical University,Guiyang,Guizhou 550025,China;不详)
出处 《中国预防医学杂志》 CAS CSCD 北大核心 2022年第8期601-607,共7页 Chinese Preventive Medicine
基金 贵州省卫生健康委科学技术基金项目(gzwjkj20191214) 中国健康促进基金会博士联盟项目(横向课题)。
关键词 高密度脂蛋白胆固醇 血脂 骨质疏松 骨密度 体质量指数 HDL cholesterol Blood lipids Osteoporosis Bone mineral density Body mass index
  • 相关文献

参考文献5

二级参考文献56

  • 1Mundy G,Garrett R,Harris S,Chan J Chen D Rossini G Boyce B Zhao M Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins[J].Science,1999,(5446):1946-1949.doi:10.1126/science.286.5446.1946. 被引量:1
  • 2Fisher JE,Rogers MJ,Halasy JM,Luckman SP Hughes DE Masarachia PJ Wesolowski G Russell RG Rodan GA Reszka AA. Alendronate mechanism of action:geranylgeraniol,an inter-mediate in the mevalonate pathway,prevents inhibition of osteo-clast formation,bone resorption,and kinase activation in vitro[J].Proceedings of the National Academy of Sciences(USA),1999.133-138. 被引量:1
  • 3Chen JS,Sambrook PN. Antiresorptive therapies for osteoporosis:a clinical overview[J].Nat Rev Endocrinol,2011.81-91. 被引量:1
  • 4Cruz AC,Gruber BL. Statins and osteoporosis:can these lipid-lowering drugs also bolster bones[J].Cleveland Clinic Journal of Medicine,2002.277-278,280-282,287-288. 被引量:1
  • 5Huang W,Shang WL,Li DH,Wu WW Hou SX. Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4[J].Molecular and Cellular Biochemistry,2012.71-77. 被引量:1
  • 6Tanriverdi HA,Barut A,Sarikaya S. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women[J].European Journal of Epidemiology,2004.1105-1112. 被引量:1
  • 7Lupattelli G,Scarponi AM,Vaudo G,Siepi D Roscini AR Gemelli F Pirro M Latini RA Sinzinger H Marchesi S Mannarino E. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women[J].Metabolism-Clinical and Experimental,2004.744-748. 被引量:1
  • 8Bauer DC,Mundy GR,Jamal SA,Black DM Cauley JA Ensrud KE van der Klift M Pols HA. Use of statins and fracture:results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials[J].Archives of Internal Medicine,2004,(2):146-152.doi:10.1001/archinte.164.2.146. 被引量:1
  • 9Bakhireva LN,Shainline MR,Carter S,Robinson S Beaton SJ Nawarskas JJ Gunter MJ. Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women[J].Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,2010.879-887. 被引量:1
  • 10Montagnani A,Gonnelli S,Cepollaro C,Pacini S Campagna MS Franci MB Lucani B Gennari C. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholestero-lemic postmenopausal women:a 1-year longitudinal study[J].Bone,2003.427-433. 被引量:1

共引文献49

同被引文献38

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部